Collegium Pharmaceutical Earnings Call Highlights ADHD Growth
Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue and strong guidance may attract buying, but GAAP earnings decline could limit upside.
Market read
Earnings release provides fresh data on growth drivers and profitability, influencing investor sentiment in the biotech sector.
What to watch
Potential BELBUCA generic launch risk and high Azstarys gross-to-net may erode future cash flow.
Background
Collegium Pharmaceutical reported Q3 results, highlighted ADHD product growth, and reaffirmed 2026 guidance while noting pain portfolio pressures.
Ticker impact
Q3 earnings call disclosed record $216.3M revenue, ADHD growth, and 2026 guidance of $825M-$855M, plus a $50M buyback tranche.
potential modest upside as market prices in ADHD growth and buyback, tempered by profit margin pressure
Revenue beat and strong guidance on core ADHD products outweighs GAAP profit decline; investors may bid the stock higher.
Market effects
ADHD pharmaceutical segment may see increased investor interest, benefiting peers with similar pipelines.
U.S. biotech sector could see modest lift in the day following the release.
Limited to U.S. and international investors tracking ADHD drug market trends.
Counterpoint
Profit margin compression and generic competition could pressure the stock despite revenue growth.
Key entities
- companyCollegium Pharmaceutical Inc.
U.S.-listed pharmaceutical company focusing on ADHD and pain management.



